share_log

騰盛博藥-B：截至2024年6月30日止六個月之中期業績公告

BRII-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Aug 19 19:30

Summary by Futu AI

腾盛博药-B（BRII-B）公布截至2024年6月30日止六個月的中期業績，現金及現金等價物減少6.9%，主要因日常營運及研發活動支出增加所致。同期，其他收入減少17.5%，主要由於政府補助收入減少。研發開支減少37.6%，主要歸因於管線排序及組織優化。行政開支亦減少23.5%，而期內虧損增加43.9%，主要因金融資產公允價值虧損所致。其他綜合收益減少80.6%，主要是匯兌差額收益減少。公司繼續推進乙型肝炎病毒功能性治癒項目，並獲得中國國家藥品監督管理局CDE的IND許可，進行多中心2期研究。公司三個臨床階段HBV項目均已獲得突破性治療品種認定。合作夥伴VBI進行重組，預計不會對公司財務或業務運營產生重大影響。公司亦尋求外部合作夥伴關係，推進非HBV項目。
腾盛博药-B（BRII-B）公布截至2024年6月30日止六個月的中期業績，現金及現金等價物減少6.9%，主要因日常營運及研發活動支出增加所致。同期，其他收入減少17.5%，主要由於政府補助收入減少。研發開支減少37.6%，主要歸因於管線排序及組織優化。行政開支亦減少23.5%，而期內虧損增加43.9%，主要因金融資產公允價值虧損所致。其他綜合收益減少80.6%，主要是匯兌差額收益減少。公司繼續推進乙型肝炎病毒功能性治癒項目，並獲得中國國家藥品監督管理局CDE的IND許可，進行多中心2期研究。公司三個臨床階段HBV項目均已獲得突破性治療品種認定。合作夥伴VBI進行重組，預計不會對公司財務或業務運營產生重大影響。公司亦尋求外部合作夥伴關係，推進非HBV項目。
Tengshengbo Medicine-B (BRII-B) announced its interim performance for the six months ended June 30, 2024. Cash and cash equivalents decreased by 6.9%, mainly due to increased daily operations and research and development expenses. During the same period, other income decreased by 17.5%, mainly due to a reduction in government subsidy income. Research and development expenses decreased by 37.6%, mainly due to pipeline prioritization and organizational optimization. Administrative expenses also decreased by 23.5%, while losses increased by 43.9% during the period, mainly due to fair value losses on financial assets. Other comprehensive income decreased by 80.6%, mainly due to a decrease in exchange gains. The company continues to advance its functional cure project for hepatitis B virus and has obtained IND approval from the Chinese National Medical...Show More
Tengshengbo Medicine-B (BRII-B) announced its interim performance for the six months ended June 30, 2024. Cash and cash equivalents decreased by 6.9%, mainly due to increased daily operations and research and development expenses. During the same period, other income decreased by 17.5%, mainly due to a reduction in government subsidy income. Research and development expenses decreased by 37.6%, mainly due to pipeline prioritization and organizational optimization. Administrative expenses also decreased by 23.5%, while losses increased by 43.9% during the period, mainly due to fair value losses on financial assets. Other comprehensive income decreased by 80.6%, mainly due to a decrease in exchange gains. The company continues to advance its functional cure project for hepatitis B virus and has obtained IND approval from the Chinese National Medical Products Administration CDE to conduct a multi-center Phase 2 study. The company's three clinical stage HBV projects have all received breakthrough therapy designations. Partner VBI is restructuring and is not expected to have a significant impact on the company's financial or business operations. The company is also seeking external partnerships to advance non-HBV projects.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated